stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.
Company profile
Ticker
STOK
Exchange
Website
CEO
Edward Kaye
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ASOthera Pharmaceuticals, Inc.
SEC CIK
Corporate docs
IRS number
471144582
STOK stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
11 Apr 24
8-K
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
28 Mar 24
424B5
Prospectus supplement for primary offering
28 Mar 24
FWP
Free writing prospectus
27 Mar 24
424B5
Prospectus supplement for primary offering
26 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001
25 Mar 24
8-K
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
25 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
14 Dec 23
Latest ownership filings
SC 13D/A
Skorpios Trust
18 Apr 24
4
Change in insider ownership
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Barry Ticho
3 Apr 24
4
Huw M. Nash
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Jonathan Allan
1 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Stephen J Tulipano
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 190.55 mm | 190.55 mm | 190.55 mm | 190.55 mm | 190.55 mm | 190.55 mm |
Cash burn (monthly) | 694.33 k | (no burn) | 9.08 mm | 9.36 mm | 5.75 mm | 6.90 mm |
Cash used (since last report) | 4.64 mm | n/a | 60.70 mm | 62.61 mm | 38.47 mm | 46.13 mm |
Cash remaining | 185.90 mm | n/a | 129.85 mm | 127.94 mm | 152.07 mm | 144.42 mm |
Runway (months of cash) | 267.7 | n/a | 14.3 | 13.7 | 26.4 | 20.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 99 |
Opened positions | 13 |
Closed positions | 9 |
Increased positions | 40 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 489.59 bn |
Total shares | 47.68 mm |
Total puts | 15.10 k |
Total calls | 270.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Skorpios Trust | 14.44 mm | $153.54 bn |
RTW Investments | 4.39 mm | $46.67 bn |
Redmile | 3.96 mm | $42.04 bn |
Cowen And | 3.72 mm | $39.56 bn |
MS Morgan Stanley | 2.92 mm | $31.05 bn |
FMR | 2.33 mm | $24.72 bn |
BLK Blackrock | 2.29 mm | $24.38 bn |
Baker Bros. Advisors | 2.13 mm | $22.64 bn |
Vanguard | 1.61 mm | $17.08 bn |
Cowen Financial Products | 1.25 mm | $11.52 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Skorpios Trust | Common Stock | Sell | Dispose S | Yes | No | 11.6 | 3,600,000 | 41.76 mm | 10,843,681 |
1 Apr 24 | Huw M. Nash | Common Stock | Sell | Dispose S | No | Yes | 13.61 | 400 | 5.44 k | 0 |
1 Apr 24 | Huw M. Nash | Common Stock | Sell | Dispose S | No | Yes | 13.2247 | 60,929 | 805.77 k | 400 |
1 Apr 24 | Huw M. Nash | Common Stock | Option exercise | Acquire M | No | No | 0.4 | 50,000 | 20.00 k | 61,329 |
1 Apr 24 | Huw M. Nash | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.4 | 50,000 | 20.00 k | 96,000 |
1 Apr 24 | Ticho Barry | Common Stock | Sell | Dispose S | No | Yes | 13.2277 | 9,426 | 124.68 k | 2,485 |
1 Apr 24 | Ticho Barry | Common Stock | Option exercise | Acquire M | No | No | 0.6 | 442 | 265.20 | 11,911 |
1 Apr 24 | Ticho Barry | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.6 | 442 | 265.20 | 80,000 |
28 Mar 24 | Jonathan Allan | Common Stock | Sell | Dispose S | No | Yes | 13.81 | 100 | 1.38 k | 2,598 |
28 Mar 24 | Jonathan Allan | Common Stock | Sell | Dispose S | No | Yes | 13.1888 | 5,026 | 66.29 k | 2,698 |
News
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
11 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Apr 24
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
4 Apr 24
Cantor Fitzgerald Reiterates Overweight on Stoke Therapeutics
4 Apr 24
Press releases
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
17 Apr 24
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
4 Apr 24
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
27 Mar 24
Stoke Therapeutics Announces Proposed Public Offering
26 Mar 24